Rontalizumab ELISA Kit

Catalog No.

KDB94502

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

78.125 - 5,000 ng/mL

Sensitivity

33.12 ng/mL

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

RhuMAB IFNalpha, CAS: 948570-30-7

S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases., PMID:33748735

Biologics targeting type I interferons in SLE: A meta-analysis and systematic review of randomised controlled trials., PMID:32960720

Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations., PMID:32237942

Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?, PMID:28765121

Interferon targeted therapies in systemic lupus erythematosus., PMID:32185249

From mechanism to therapies in systemic lupus erythematosus., PMID:28118202

Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?, PMID:27497254

Update on clinical trials in systemic lupus erythematosus., PMID:27314466

Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus., PMID:27270345

Structural basis of the broadly neutralizing anti-interferon-α antibody rontalizumab., PMID:26099203

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)., PMID:26038091

Targeting interferons in systemic lupus erythematosus: current and future prospects., PMID:25940912

Type I interferon blockade in systemic lupus erythematosus: where do we stand?, PMID:24344319

Interferon α-targeted therapy., PMID:23994795

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study., PMID:22833362

Document Download

Rontalizumab ELISA Kit.pdf